Corporate Profile

Laboratory Corporation of America® Holdings, an S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $5.8 billion in 2013, over 34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more than 4,000 tests ranging from routine blood analyses to reproductive genetics to companion diagnostics. LabCorp furthers its scientific expertise and innovative clinical testing technolo... More >>

Recent NewsMore >>
09/12/14LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 12, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today that for the period of September 12, 2014 to March 11, 2015, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the terms of the Zero Coupon Notes, accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading... 
Printer Friendly Version
09/04/14LabCorp’s Enlighten Health Launches Innovative Genomics Initiative
Enlighten Health Genomics Aims to Make Genetic Profiles a Routine Part of Clinical Decisions BURLINGTON, N.C.--(BUSINESS WIRE)--Sep. 4, 2014-- Laboratory Corporation of America® Holdings (LabCorp®; NYSE: LH) announced today the launch of Enlighten Health Genomics, a new business that builds on the diagnostic potential of Next-Generation Sequencing (NGS) technology. Enlighten Health Genomics is part of LabCorp’s Enlighten HealthSM, an innovatio... 
Printer Friendly Version
08/19/14LabCorp Announces the Availability of InformaSeqSM Non-Invasive Prenatal Test
BURLINGTON, N.C.--(BUSINESS WIRE)--Aug. 19, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the availability of the informaSeq Prenatal Test. The informaSeq Prenatal Test is an advanced, non-invasive, next-generation prenatal screening assay that can assess risk for multiple fetal chromosomal aneuploidies, or abnormalities in the number of chromosomes, from a single maternal blood draw. There are te... 
Printer Friendly Version
07/18/14Laboratory Corporation of America® Holdings Announces 2014 Second Quarter Results and Increases 2014 EPS Guidance
Sales of $1.52 billion Diluted EPS of $1.64; Adjusted EPS of $1.84 Operating Cash Flow of $207 million; Free Cash Flow of $159 million 2014 Adjusted EPS guidance raised to $6.50 - $6.75 BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 18, 2014-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced results for the quarter ended June 30, 2014. Second Quarte... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
LH (Common)
Change Stock is Down 1.62
Intraday High$106.04
Intraday Low$104.24
Data as of 09/22/14
4:06 p.m. ET
Minimum 20 minute delay
Refresh quote

Reports & Performance

2013 Annual Report

2012 Annual Report

2011 Annual Report

2010 Annual Report

2009 Annual Report

2008 Annual Report

2007 Annual Report

2006 Annual Report

Latest Earnings Release